Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey

INTRODUCTION: Were the participants of the EMPA-REG OUTCOME trial representative of patients receiving empagliflozin in clinical practice? The aim of the present study was to examine the prevalence of cardiovascular disease (CVD) in type 2 diabetes patients starting empagliflozin treatment in routin...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Diabetes Ther
Egile Nagusiak: Eliasson, Björn, Ekelund, Jan, Amberntsson, Rikard, Miftaraj, Mervete, Svensson, Ann-Marie
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer Healthcare 2019
Gaiak:
Brief Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6612325/
https://ncbi.nlm.nih.gov/pubmed/31089969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-019-0632-4
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak